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Conclusions: The bootstrap provides a statistical analysis of the 
uncertainty in the estimated dose-response relation. It suggests likely 
values of D50 and y (m), their confidence intervals, and how they 
interrelate for each model. Finally, it can be used to evaluate to what 
extent data supports one model over another. Both data sets 
considered here provided fairly strong support to the Lyman model 
over the Poisson-based model.  
   
PD-0189   
Multivariate NTCP models for radiation-induced hypothyroidism 
L. Cella1, R. Liuzzi1, M. Conson2, V. D'Avino1, M. Salvatore2, R. Pacelli2 
1Institute of Biostructures and Bioimaging National Council of 
Research (CNR), Radiation Oncology, Naples, Italy  
2Department of Diagnostic Imaging and Radiation Oncology Federico II 
University School of Medicine, Radiation Oncology, Naples, Italy  
 
Purpose/Objective: Radiation-induced hypothyroidism (RHT) is a 
frequent side effect after therapeutic irradiation of the cervical 
region and it has been described in patients undergoing radiation 
therapy (RT) for different neoplasms such as lymphoma, head-and-
neck cancer and breast cancer. Purpose of this work is to develop 
multivariate normal tissue complication probability (NTCP) models for 
RHT and to compare them with already existing NTCP models for RHT. 
Materials and Methods: Fifty-three patients treated at our 
department with sequential chemo-radiotherapy for Hodgkin’s 
lymphoma (HL) were retrospectively reviewed for RHT events. Clinical 
information along with thyroid gland dose distribution parameters 
were collected and their correlation to RHT was analyzed by 
Spearman’s rank correlation coefficient (Rs). Multivariate logistic 
regression method using resampling methods (bootstrapping) was 
applied to select model order and parameters for NTCP modeling. 
Model performance was evaluated through the area under the receiver 
operating characteristic curve (AUC). Models were tested against 
external published data on RHT and compared with other published 
NTCP models. 
Results: When we express the thyroid volume exceeding XGy as a 
percentage (Vx(%)), a two-variable NTCP model including V30(%) and 
gender (female=0, male=1) was suggested as the optimal predictive 
model for RHT (Rs= 0.615, p<0.001. AUC= 0.87). Conversely, when 
absolute thyroid volume exceeding X Gy (Vx(cc)) was analyzed, an 
NTCP model based on 3 variables including V30(cc), thyroid gland 
volume (VT) and gender was selected as the most predictive model 
(Rs=0.630, p<0.001, AUC= 0.85).The three-variable model have a 
better performance (AUC= 0.914, 95%CI0.760-0.984) when tested on 
an external cohort characterized by large inter-individuals variation in 
thyroid volumes. The risk of RHT is given by:  
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The behavior of the NTCP for male and female is represented in figure 
1. 
A comparable performance was found between our model and that 
proposed in the literature based on thyroid gland mean dose and 
volume (p= 0.264). 
 
 
 
Figure 1 
 
 
Conclusions: The absolute volume of thyroid gland exceeding 30 Gy in 
combination with thyroid gland volume and gender provide an NTCP 
model for RHT with improved prediction capability not only within our 
patient population but also on an external cohort. 
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Purpose/Objective: Radiation-induced lung damage (RILD) is one 
ofthe most important dose-limiting toxicities in the treatment of lung 
cancer patients. Prediction models are still unsatisfactory, partly 
because clinical toxicity endpoints such as dyspnea are influenced by 
many parameters and difficult to quantify objectively. Furthermore, 
interactions between drugs and radiotherapy (RT) are difficult to 
assess. We therefore evaluated RILD more objectively, quantitatively 
and on a continuous scale measuring the regional lung tissue density 
changes per voxel. 
Materials and Methods: Multiple treatment regimens of lung cancer 
(both SCLC and NSCLC) were retrospectively analysed: radiotherapy 
alone, sequential and concurrent chemo-radiotherapy with or without 
the addition of the targeted agent cetuximab. Follow-up CT scans up 
to 6 months (range, 2-6 months) after the end of treatment were co-
registered using deformable registration to baseline CT scans. CT 
density changes (expressed in Hounsfield Units) in the lungs were 
correlated to the RT dose delivered in every part (i.e. voxel) of the 
lungs. 
Results: CT scans from 119 lung cancer patients were studied. 
Patients received a mean dose of 60 Gy (range 45-80 Gy) to the 
tumor. For the different treatment modalities: patients treated only 
with RT (N=19), sequential chemo-RT (N=30), concurrent chemo-RT 
(N=51), concurrent chemo–RT with cetuximab (N=19), the absolute 
increase in HU for voxels receiving between 40 and 50 Gy was 27 ±26, 
38 ± 45, 29 ± 38, and 54 ± 33 HU, respectively. Furthermore, dose-
response curves were linear in the dose-region between 0 and 80 Gy 
with a slope expressed as a lung density increase per dose (HU/Gy), of 
0.7 ± 0.7, 1.2± 1.2, 1.1 ± 1.2, and 1.6 ± 1.0 HU/Gy. Hence, the dose-
response curve for the group treated with the targeted agent 
cetuximab showed more susceptibility for RILD (P < 0.03) compared to 
(chemo-) radiotherapy. 
Conclusions: CT density changes allow quantitative non-invasive 
assessment of lung toxicity, giving complementary information to 
standard used clinical endpoints. Patients receiving cetuximab showed 
a higher increase in HU and a significantly larger dose response 
compared with the patients not receiving cetuximab.  
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